The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Belantamab mafodotin in R/R myeloma and methods of reducing ocular toxicity
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the efficacy of belantamab mafodotin in relapsed/refractory multiple myeloma (R/R MM) and efforts to limit the ocular toxicity associated with this agent. Dr Popat explains how active surveillance and treatment interruptions are important, and that obtaining information directly from patients with questionnaires may also help with predicting keratopathy and guiding treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
